Rifaximin Versus Lactulose in Renal Failure
Overview
The purpose of this study is to evaluate patients with cirrhosis of the liver and renal failure and determine if the administration of rifaximin as compared to lactulose is associated with less frequent and/or slower progression to severe hepatic encephalopathy. If one is associated with lower blood ammonia levels. And, if one is associated with lower breath hydrogen and methane levels.
Full Title of Study: “A Randomized Comparison of Rifaximin Versus Lactulose in Hospitalized Cirrhotic Patients With Progressive Renal Failure”
Study Type
- Study Type: Interventional
- Study Design
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Primary Purpose: Treatment
- Masking: None (Open Label)
- Study Primary Completion Date: July 2009
Interventions
- Drug: Rifaximin
- 400 mg orally
- Drug: Lactulose
- 20 grams titrate to 2-3 bowel movements in one day
Arms, Groups and Cohorts
- Experimental: A
- 35 patients receiving rifaximin
- Experimental: B
- 35 patients receiving lactulose
Clinical Trial Outcome Measures
Primary Measures
- slower progression to severe hepatic encephalopathy, stage 3 or 4
- Time Frame: during hospitalization
Participating in This Clinical Trial
Inclusion Criteria
- cirrhosis of liver of any etiology – progressive renal failure – stage 0-2 hepatic encephalopathy Exclusion Criteria:
- pregnant women
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: 65 Years
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Weill Medical College of Cornell University
- Provider of Information About this Clinical Study
- Sponsor
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.